Aap Implantate AG Reports €6.2 Million in Sales for H1 2025

aap Implantate AG has announced sales of €6.2 million for the first half of 2025. The company reveals that its human clinical trial for Silver Antibacterial Technology is nearing completion, paving the way for regulatory approval. Growth in the EMEA region normalized by 11% after excluding one-time effects, with the APAC region showing strong growth of 82%. US tariffs introduced in April were effectively managed, minimizing their impact.

Despite challenges, such as geopolitical uncertainties and fragile supply chains, aap maintained its operating base. Notable regional performance included an 8% increase in Germany and 36% in South Africa within EMEA. Brazil's launch of LOQTEQ® foot systems contributed to a 37% growth in LATAM, proving successful amid challenges in Mexico and Colombia.

Operational adjustments and price strategies in the USA resulted in stabilization, achieving over USD 0.3 million in sales in June. The company plans to increase orders in the latter half of 2025, with ongoing investments and sales initiatives.